STAT3 in hepatocellular carcinoma: new perspectives

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Cancer immunology
• Signal transduction pathways

Background:

• Chronic liver damage and inflammation are key drivers of hepatocellular carcinoma (HCC) development.
• HCC cells interact with inflammatory and stromal cells through cytokine/chemokine signaling, promoting tumor growth and inhibiting anti-cancer immunity.
• Signal transducer and activator of transcription 3 (STAT3) plays a role in mediating these interactions and influencing tumor formation.

Purpose of the Study:

• To discuss the dual role of cytokine-activated STAT3 in hepatocellular carcinoma (HCC).
• To explore both the tumor-promoting and tumor-suppressive functions of STAT3 in the context of HCC.
• To analyze the complex involvement of STAT3 in liver cancer progression.

Main Methods:

• Review of existing literature on STAT3 signaling in HCC.
• Analysis of studies investigating STAT3 activation by cytokines.
• Discussion of experimental evidence for STAT3's oncogenic and tumor-suppressive roles in liver cancer.

Main Results:

• STAT3 activation is frequently observed in HCC and linked to tumor-promoting activities like angiogenesis and invasiveness.
• Reciprocal interactions mediated by STAT3 between cancer and stromal cells contribute to a pro-tumorigenic microenvironment.
• Contradictory findings suggest STAT3 may also possess tumor-suppressive functions in certain contexts of HCC.

Conclusions:

• STAT3 exhibits a complex and context-dependent role in hepatocellular carcinoma (HCC).
• Understanding the dual functions of STAT3 is crucial for developing effective HCC therapies.
• Further research is needed to fully elucidate the mechanisms underlying STAT3's tumor-promoting and tumor-suppressive effects in HCC.